Drugs in R&D

Cardiovascular Safety Profile of Dapoxetine during the Premarketing Evaluation
pp. 1-11(11)
Authors: Kowey, Peter R.; Mudumbi, Ramagopal V.; Aquilina, Joseph W.; DiBattiste, Peter M.

Intra-Articular Injections for the Treatment of Osteoarthritis: Focus on the Clinical Use of Hyaluronic Acid
pp. 13-27(15)
Authors: Iannitti, Tommaso; Lodi, Daniele; Palmieri, Beniamino

Different Doses of Palonosetron for the Prevention of Postoperative Nausea and Vomiting in Children Undergoing Strabismus Surgery
pp. 29-36(8)
Authors: Bicer, Cihangir; Aksu, Recep; Ulgey, Ayse; Madenoglu, Halit; Dogan, Hakki; Yildiz, Karamehmet; Boyaci, Adem

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole
pp. 37-51(15)
Authors: Martin, Paul; Oliver, Stuart; Robertson, Jane; Kennedy, Sarah-Jane; Read, Jessica; Duvauchelle, Thierry

Comparison of Dissolution Profiles and Serum Concentrations of Two Lamotrigine Tablet Formulations
pp. 53-60(8)
Authors: Lalic, Mladena; Pilipovic, Ana; Golocorbin-Kon, Svetlana; Gebauer-Bukurov, Ksenija; Bozic, Ksenija; Mikov, Momir; Cvejic, Jelena

Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of One US-Marketed and Two European-Marketed Epoetin Alfas: A Randomized Prospective Study
pp. 61-75(15)
Authors: Lissy, Michael; Ode, Marité; Roth, Karsten

Pharmacokinetic Profile of Lesogaberan (AZD3355) in Healthy Subjects: A Novel GABA_B-Receptor Agonist Reflux Inhibitor
pp. 77-83(7)
Authors: Niazi, Mohammad; Skrtic, Stanko; Ruth, Magnus; Holmberg, Ann A.

Brentuximab Vedotin
pp. 85-95(11)

Consistent Biochemical Data are Essential for Comparability of Botulinum Toxin Type A Products
pp. 97-98(2)
Author: Pickett, Andy

Author's Reply
pp. 98-99(2)
Authors: Frevert, Jürgen